Price$19.03+0.75 (+4.13%)
01:30 PM03:15 PM
News · 26 weeks61+50%
2025-11-092026-05-03
Mix1490d
- SEC Filings5(36%)
- Other3(21%)
- Earnings3(21%)
- Insider2(14%)
- Leadership1(7%)
Latest news
25 items- SECSEC Form 10-Q filed by Azenta Inc.10-Q - Azenta, Inc. (0000933974) (Filer)
- SECAzenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Azenta, Inc. (0000933974) (Filer)
- PRAzenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029FY'26 total reported revenue from continuing operations to range between approximately $603 to $621 millionFY'26 organic revenue is now expected to range from down approximately 2% to up 1%, compared to prior guidance of 3% to 5% growthFY'26 Adjusted EBITDA margin is now expected to range from down approximately 125 basis points to flat, compared to prior expectations of approximately 300 basis points of expansionLong-range plan timing updated to 2029 versus 2028 before in connection with revised 2026 guidance. Market opportunities, strategic priorities, and value creation framework remain intact.BURLINGTON, Mass., May 5, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financi
- INSIDERPresident Multiomics Martin William E. Iii was granted 17,790 units of Common (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- PRAzenta Announces Fiscal 2026 Second Quarter Conference Call and WebcastBURLINGTON, Mass., April 29, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2026 earnings which ended on March 31, 2026, on Wednesday, May 6, 2026, before the market opens.The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 6, 2026, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 7, 2026.About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactf
- INSIDERSEC Form 3 filed by new insider Martin William E. Iii3 - Azenta, Inc. (0000933974) (Issuer)
- SECAzenta Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Azenta, Inc. (0000933974) (Filer)
- PRAzenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics ExecutionBURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive Officer.This appointment is aimed at accelerating execution of Azenta's Multiomics long-range plan, outlined at its December 2025 Investor Day, with a continued focus on scaling global synthesis capabilities, strengthening operational excellence, enhancing commercial discipline, and driving profitable growth across the integrated Multiomics platform to support broader market ado
- SECAzenta Inc. filed SEC Form 8-K: Other Events8-K - Azenta, Inc. (0000933974) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Azenta Inc.SCHEDULE 13G/A - Azenta, Inc. (0000933974) (Subject)
- SECAzenta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Azenta, Inc. (0000933974) (Filer)
- PRAzenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository CapabilitiesBURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a leading provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom. The total consideration was GBP 20.5 million, net of cash and inclusive of up to GBP 1.8 million in contingent consideration upon the completion of certain milestones. The acquisition strengthens Azenta's ability to deliver end-to-end l
- PRAzenta to Participate in Raymond James 47th Annual Institutional Investor ConferenceBURLINGTON, Mass., Feb. 24, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in Raymond James 47th Annual Institutional Investor Conference, on Tuesday March 3rd, 2026, which includes a presentation beginning at 4:00 pm ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta p
- PRAzenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research InfrastructureBURLINGTON, Mass., Feb. 9, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduct cutting-edge scientific experiments in space. This collaboration aims to harness the unique benefits of the microgravity environment to accelerate discovery and innovation in life sciences, including participation in the recently launched EGGS-2 (Early Gen micro-Gravity Service) mission, developed in collaboration with Orbital Paradigm. The mission was intended to test and advance the performance of Frontier's SpaceLab Mk 2 research platform under real launch and spaceflight conditions. This co
- INSIDERAmendment: SEC Form 4 filed by Director Cornog William L4/A - Azenta, Inc. (0000933974) (Issuer)
- INSIDERDirector Nova Tina Susan was granted 5,663 units of Common, increasing direct ownership by 56% to 15,772 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERSEC Form 4 filed by Director Cornog William L4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERSEC Form 4 filed by Director Madaus Martin D4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERDirector Doshi Dipal was granted 5,663 units of Common, increasing direct ownership by 140% to 9,703 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERDirector Casal Frank was granted 7,243 units of Common, increasing direct ownership by 50% to 21,803 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERDirector Mclaughlin Erica was granted 5,663 units of Common, increasing direct ownership by 34% to 22,521 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERSEC Form 4 filed by Director Davis Robyn C4 - Azenta, Inc. (0000933974) (Issuer)
- SECSEC Form 10-Q filed by Azenta Inc.10-Q - Azenta, Inc. (0000933974) (Filer)
- SECAzenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Azenta, Inc. (0000933974) (Filer)
- PRAzenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale and the entry into a definitive agreement to sell the business, which is expected to close on or before March 31, 2026. Quarter Ended Dollars in millions, except per share data December 31, September 30, December31, Change 2025 2025 2024 (1) Prior Qtr Prior Yr. Revenue from Continuing Operations $ 149 $ 159 $ 147 (7) % 1 % Organ
AZTA FAQ
6 questionsWhat does Azenta Inc. do?
Azenta, Inc. provides manufacturing automation solutions for the semiconductor industry, and life science sample-based services and solutions for the life sciences market worldwide. The company operates in two segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated ultra-cold storage systems and consumables, including racks, tubes, caps, plates, and foils; instruments, such as labeling, bar coding, capping, de-capping, auditing, sealing, peeling, piercing tubes, and plates. The Life Sciences Services segment offers genomic services and...Where does AZTA stock trade?
Azenta Inc. (AZTA) is listed on NASDAQ.What sector and industry is AZTA in?
Azenta Inc. operates in the Technology sector, Industrial Machinery/Components industry.What are analysts saying about AZTA?
Azenta Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform on 2026-01-05. Recent price targets range from $3500.00 to $4400.00.What companies are similar to AZTA?
Notable peers in the same industry include ASML (ASML Holding N.V. New York Registry Shares), LRCX (Lam Research Corporation), TMO (Thermo Fisher Scientific Inc), DE (Deere & Company), ETN (Eaton Corporation PLC). Compare AZTA side-by-side with any of them on Quantisnow.How can I track AZTA on Quantisnow?
Quantisnow aggregates Azenta Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AZTA to receive live email and push alerts on every new disclosure.